Scientists develop proprietary technology, addressing issues on the rise with unregulated CBD- and Delta-8-THC based products
Given the prohibited status of Delta-9-THC in 22 states, usage of Delta-8-THC in particular, and CBD have become prevalent in the marketplace due to their similar but less psychoactive biological effects.
These products are highly unregulated and have led to concerns regarding cannabinoid composition and overall safety. Additionally, usage of these products has made drug testing complicated to interpret because the chemical structures are similar and cannot be differentiated by standard drug testing methods. Luxor Scientific, LLC and Clearwater BioTech, LLC are working together to tackle these concerns with hemp-derived cannabinoid products. Luxor Scientific has designed the CannabisConfirm panel, a urine testing method to provide evidence for employers and healthcare providers as to whether an individual has consumed Delta-9-THC, Delta-8-THC, CBD and/or other cannabinoids. Compared to traditional laboratory practices, CannabisConfirm gives practitioners and employers the ability to identify legal versus illicit cannabis use.
Sister company, Clearwater BioTech is an environmental and product testing laboratory that provides testing for all sectors of the cannabis and natural products market. Commercially available Delta-8 products are created in labs from CBD using a broad mixture of chemicals, such as pesticides, petroleum, and unknown ingredients. Farmers, product formulators, consumers, retailers, and regulators work with Clearwater Biotech to ensure the composition and safety of cannabinoid products as well as their adherence to local and national regulations.
